BR112020003735A2 - método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais - Google Patents

método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais Download PDF

Info

Publication number
BR112020003735A2
BR112020003735A2 BR112020003735-4A BR112020003735A BR112020003735A2 BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2 BR 112020003735 A BR112020003735 A BR 112020003735A BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2
Authority
BR
Brazil
Prior art keywords
viral
arginine
mimetic
analog
tranexamic acid
Prior art date
Application number
BR112020003735-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Murdock
Ronnea MURDOCK
W. Paul Stewart
Original Assignee
Anti-Viral Technologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anti-Viral Technologies, Llc filed Critical Anti-Viral Technologies, Llc
Publication of BR112020003735A2 publication Critical patent/BR112020003735A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020003735-4A 2017-08-27 2018-08-09 método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais BR112020003735A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US62/550656 2017-08-27
US201862664555P 2018-04-30 2018-04-30
US62/664555 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Publications (1)

Publication Number Publication Date
BR112020003735A2 true BR112020003735A2 (pt) 2020-09-01

Family

ID=65525881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003735-4A BR112020003735A2 (pt) 2017-08-27 2018-08-09 método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais

Country Status (11)

Country Link
US (3) US11413279B2 (cg-RX-API-DMAC7.html)
EP (2) EP4681713A2 (cg-RX-API-DMAC7.html)
JP (3) JP2020531586A (cg-RX-API-DMAC7.html)
KR (1) KR102706114B1 (cg-RX-API-DMAC7.html)
CN (1) CN111315374A (cg-RX-API-DMAC7.html)
AU (2) AU2018324427B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003735A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073685A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002156A (cg-RX-API-DMAC7.html)
WO (1) WO2019045989A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001472B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220249416A1 (en) * 2019-10-29 2022-08-11 Tranexamic Technologies, Llc Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
WO2021162879A1 (en) * 2020-02-14 2021-08-19 Tranexamic Technologies, Llc Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs
JP7830159B2 (ja) * 2021-02-26 2026-03-16 ライオン株式会社 コロナウイルスの細胞侵入抑制剤
EP4659805A3 (en) 2022-02-09 2026-04-01 Galen Limited Concentrated injectable tranexamic acid compositions and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524971T2 (de) * 1994-10-28 2002-08-29 Vitaleech Bioscience N.V., Rotterdam Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
AU1773600A (en) * 1998-12-21 2000-07-12 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) * 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) * 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
AU2003272974A1 (en) * 2002-10-11 2004-05-04 Daiichi Pharmaceutical Co., Ltd. Anti-influenza virus agent
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN103405384B (zh) * 2013-09-01 2015-05-13 吴静 氨甲环酸的药物组合物

Also Published As

Publication number Publication date
WO2019045989A1 (en) 2019-03-07
US20260007649A1 (en) 2026-01-08
US11413279B2 (en) 2022-08-16
AU2024203839A1 (en) 2024-06-27
EP4681713A2 (en) 2026-01-21
JP2023123440A (ja) 2023-09-05
CN111315374A (zh) 2020-06-19
MX2023009499A (es) 2023-08-23
AU2018324427A1 (en) 2020-04-09
CA3073685A1 (en) 2019-03-07
JP2020531586A (ja) 2020-11-05
EP3672584A1 (en) 2020-07-01
EP3672584A4 (en) 2021-05-05
US20200323837A1 (en) 2020-10-15
KR20200052310A (ko) 2020-05-14
ZA202001472B (en) 2022-05-25
KR102706114B1 (ko) 2024-09-11
US20220288050A1 (en) 2022-09-15
MX2020002156A (es) 2020-07-20
JP2025166032A (ja) 2025-11-05
AU2018324427B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
US20260007649A1 (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
US9387227B2 (en) Method for treatment of sores and lesions of the skin
SA96160590B1 (ar) تركيبة صيدلانية
JP7399976B2 (ja) Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
BR122023026038A2 (pt) Usos de um ácido e de um modulador de autofagia e de lipofagia
WO2021198940A1 (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
US20120071498A1 (en) Therapeutic composition to treat lesions caused by herpes simplex virus
BR112017024399B1 (pt) Composição farmacêutica antiviral de uso tópico
DK2374461T3 (en) Piroxicam for the prophylactic and therapeutic treatment of herpes infections
PT653939E (pt) Utilizacao de um veneno de himenoptero para o fabrico de um medicamento para o tratamento de infeccoes por virus de adn
Wu et al. IcyHot analgesic topical cream limits cardiac injury in rodents
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
US11819508B2 (en) Miltefosine for the treatment of viral infections including covid-19
US20250177335A1 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for modulating autophagy and lipophagy
BR102020014414B1 (pt) Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes
EP4734970A1 (en) Composition comprising hinokitiol and zinc salt for use in the treatment of herpes labialis
WO2024236145A1 (en) Long term treatment of hair loss
US20230414557A1 (en) New therapy concept for the treatment of corona infections, especially covid-19 infections
WO2021224659A1 (es) Composición farmacéutica y kit-de-partes para ser usados frente a infecciones causadas por corona virus
CN114929212A (zh) 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合
BR102020014414A2 (pt) Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes
JP2009542703A (ja) 口唇ヘルペス(単純疱疹)の局所治療のための抗ウイルス組成物およびそれを用いる方法
Iankova P362 Topical acyclovir in the treatment of erythema annulare centrifugum
US20160199318A1 (en) Anti-Viral Compound and Composition

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]